AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12771595 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifier
Number of subjects: 11
Study 12771595 — intervention group
Group type: COMPARATOR
Intervention: Heat and moisture exchanger
Number of subjects: 11
Study 10665556 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week multidisciplinary rehabilitation programme (18 visits)
Number of subjects: 200
Study 10665556 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 200
Study 9820371 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis (heater probe, bipolar electrocoagulation, or injection sclerosis)
Number of subjects: 155
Study 9820371 — intervention group
Group type: COMPARATOR
Intervention: Medical‐surgical treatment
Number of subjects: 155
Study 9820371 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis
Number of subjects: 155
Study 8022739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of methylprednisolone (500 mg for three consecutive days)
Number of subjects: 32
Study 8022739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of methylprednisolone (500 mg for three consecutive days)
Number of subjects: 32
Study 2555473 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 35
Study 2555473 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-infected women
Number of subjects: 35
Study 1101910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (an antiandrogen)
Number of subjects: 0
Study 1101910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesterolone (an androgen)
Number of subjects: 0
Study 1101910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31036002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette depicting a potentially more well‐implemented mental health service
Number of subjects: 153
Study 31036002 — intervention group
Group type: COMPARATOR
Intervention: Vignette depicting existing local psychiatric services
Number of subjects: 153
Study 28490356 — intervention group
Group type: EXPERIMENTAL
Intervention: Miriplatin/DDP‐H combination therapy
Number of subjects: 19
Study 28490356 — intervention group
Group type: COMPARATOR
Intervention: Miriplatin monotherapy
Number of subjects: 19
Study 25809331 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose CT colonography with enhanced scanning
Number of subjects: 120
Study 25809331 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose CT colonography with enhanced scanning
Number of subjects: 120
Study 25809331 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose CT colonography
Number of subjects: 120
Study 25809331 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose CT colonography
Number of subjects: 120
Study 24075764 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day
Number of subjects: 26
Study 24075764 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 21255459 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter-directed thrombolysis (group A)
Number of subjects: 60
Study 21255459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-accelerated thrombolysis (group B)
Number of subjects: 60
Study 19450614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 41
Study 19450614 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly controls
Number of subjects: 41
Study 16813489 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-expressive messages advocating testing for self-interest (own health)
Number of subjects: 0
Study 16813489 — intervention group
Group type: COMPARATOR
Intervention: Messages advocating testing for the goal of protecting one's partners
Number of subjects: 0
Study 15098379 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (Evista), one tablet daily, with or without food
Number of subjects: 7700
Study 11783326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP)
Number of subjects: 12
Study 11783326 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 9331324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion blocks using 4% lidocaine
Number of subjects: 61
Study 9331324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 61
Study 7597427 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2 infused as a single dose over 1 hour
Number of subjects: 56
Study 7597427 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel divided into three doses infused over 1 hour on 3 consecutive days
Number of subjects: 56
Study 7597427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both infusion schedules
Number of subjects: 56
Study 2512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (300mg/kg/day i.v.; max 12g) + Amikacin (36mg/kg/day i.v.; max 1,500mg)
Number of subjects: 42
Study 2512129 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (300mg/kg/day i.v.; max 12g) + Amikacin (36mg/kg/day i.v.; max 1,500mg)
Number of subjects: 42
Study 2512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Ciprofloxacin (30mg/kg/day; max 1,500mg) for four weeks after initial therapy
Number of subjects: 42
Study 31071100 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Behavioural Physiotherapy Intervention (ABPI)
Number of subjects: 28
Study 31071100 — intervention group
Group type: COMPARATOR
Intervention: Standard Physiotherapy
Number of subjects: 28
Study 28261001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract 1200 mg for 6 weeks
Number of subjects: 16
Study 28261001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25380955 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOM (Endotracheal Cardiac Output Monitor)
Number of subjects: 100
Study 25380955 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 100
Study 24100691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparrow® drug‐eluting stent (DES)
Number of subjects: 24
Study 24100691 — intervention group
Group type: COMPARATOR
Intervention: Sparrow® bare metal stent (BMS)
Number of subjects: 24
Study 21331459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac (123)I‐MIBG uptake in de novo PD
Number of subjects: 26
Study 21331459 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 21331459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular autonomic response on the Valsalva maneuver (VM)
Number of subjects: 26
Study 21331459 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure response (SBP) on head‐up tilt‐table testing (HUT)
Number of subjects: 26
Study 21331459 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure overshoot in phase IV of the VM
Number of subjects: 26
Study 18298503 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy for 2 weeks
Number of subjects: 236
Study 18298503 — intervention group
Group type: COMPARATOR
Intervention: General prenatal care (Control)
Number of subjects: 236
Study 17201647 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus aurantium (herbal phenylephrine)
Number of subjects: 28
Study 17201647 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (20 mg)
Number of subjects: 28
Study 12492451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (TD) 5 mg/day
Number of subjects: 40
Study 12492451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (TD)
Number of subjects: 40
Study 12492451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (LD)
Number of subjects: 40
Study 10791373 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus hyperthermia
Number of subjects: 358
Study 10791373 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 358
Study 9059313 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P
Number of subjects: 8
Study 9059313 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 8
Study 9059313 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline
Number of subjects: 8
Study 9059313 — intervention group
Group type: COMPARATOR
Intervention: NG-Monomethyl-L-arginine
Number of subjects: 8
Study 8110870 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucerna
Number of subjects: 62
Study 8110870 — intervention group
Group type: EXPERIMENTAL
Intervention: Precitene Diabet
Number of subjects: 62
Study 8110870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products (Glucerna and Precitene Diabet)
Number of subjects: 62
Study 2859870 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (25 mg three times daily)
Number of subjects: 15
Study 2859870 — intervention group
Group type: COMPARATOR
Intervention: Control (beta blockers and nitrates continued unchanged)
Number of subjects: 15
Study 30651294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap testing at the BHU (N = 160)
Number of subjects: 483
Study 30651294 — intervention group
Group type: EXPERIMENTAL
Intervention: Self HPV (self‐collection for HPV testing) (N = 161)
Number of subjects: 483
Study 30651294 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice between self‐collection and HPV testing and Pap test at the local BHU (N = 162)
Number of subjects: 483
Study 29846804 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 144
Study 29846804 — intervention group
Group type: COMPARATOR
Intervention: Standard Digital Mammography (DM)
Number of subjects: 144
Study 26143058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin
Number of subjects: 323
Study 26143058 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 323
Study 24977689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS)
Number of subjects: 120
Study 24977689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral stimulation (OS)
Number of subjects: 120
Study 24977689 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NNS + OS
Number of subjects: 120
Study 24977689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 22672770 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab 400 mg weekly
Number of subjects: 52
Study 22672770 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab (various doses)
Number of subjects: 52
Study 22672770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 20307678 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively arousing musical piece after a 20-minute delay
Number of subjects: 127
Study 20307678 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively arousing musical piece after a 20-minute delay
Number of subjects: 127
Study 20307678 — intervention group
Group type: COMPARATOR
Intervention: Positively arousing musical piece immediately post-learning
Number of subjects: 127
Study 20307678 — intervention group
Group type: COMPARATOR
Intervention: Negatively arousing musical piece immediately post-learning
Number of subjects: 127
Study 20307678 — intervention group
Group type: COMPARATOR
Intervention: Positively arousing musical piece after a 45-minute delay
Number of subjects: 127
Study 20307678 — intervention group
Group type: COMPARATOR
Intervention: Negatively arousing musical piece after a 45-minute delay
Number of subjects: 127
Study 18551725 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 365
Study 18551725 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 365
Study 16112299 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 357
Study 16112299 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemopoietic-cell transplantation
Number of subjects: 357
Study 12354424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy in hospitals with coronary revascularization capability
Number of subjects: 25515
Study 12354424 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytic therapy in hospitals without coronary revascularization capability
Number of subjects: 25515
Study 10519714 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment by office based paediatricians
Number of subjects: 30
Study 10519714 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral strategy
Number of subjects: 30
Study 8624234 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Micro Cleansing Tartar Control (MCTC) dentifrice
Number of subjects: 86
Study 8624234 — intervention group
Group type: COMPARATOR
Intervention: Colgate original Tartar Control (TC) dentifrice
Number of subjects: 86
Study 1970584 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F 104353 (800 micrograms inhaled)
Number of subjects: 12
Study 1970584 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg oral)
Number of subjects: 12
Study 1970584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7069504 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methionine (0.0605 mmoles/kg body weight)
Number of subjects: 0
Study 7069504 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-methionine (0.0605 mmoles/kg body weight)
Number of subjects: 0
Study 7069504 — intervention group
Group type: COMPARATOR
Intervention: L-methionine and N-acetyl-L-methionine
Number of subjects: 0
Study 7069504 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-methionine
Number of subjects: 0
Study 31615471 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-Rituximab
Number of subjects: 116
Study 31615471 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-sulfur colloid (fTcSC)
Number of subjects: 116
Study 29071979 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation of HT acupoints (HT 1, HT 3, HT 4, HT 7) at 2 Hz, 2-5 mA for 6 min
Number of subjects: 20
Study 29071979 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture stimulation of non-acupoints for 6 min
Number of subjects: 20
Study 26164674 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg naltrexone
Number of subjects: 44
Study 26164674 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 44
Study 26164674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25118085 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (Ca+Vit D, 2000mg and 1000IU/d) delivered as 2 snack bars per day for 9 weeks during Army BCT
Number of subjects: 243
Study 25118085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 23045575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 422
Study 23045575 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 422
Study 23045575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy and Physical Exercise (CBT/PE)
Number of subjects: 422
Study 23045575 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 422
Study 19998508 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant carrying ropivacaine in the gallbladder bed
Number of subjects: 60
Study 19998508 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant in the gallbladder bed
Number of subjects: 60
Study 19998508 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in the gallbladder bed
Number of subjects: 60
Study 16891384 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold 1 Hz rTMS (30 min) applied to the region with maximal tinnitus-related increase in regional cerebral blood flow
Number of subjects: 6
Study 16891384 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study 16891384 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold 1 Hz rTMS
Number of subjects: 6
Study 15530150 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 11
Study 15530150 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (1.35 g n‐3 fatty acids)
Number of subjects: 11
Study 11523612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dofetilide
Number of subjects: 15
Study 11523612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9692655 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice/day
Number of subjects: 12
Study 9692655 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg/day
Number of subjects: 12
Study 9692655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice/day
Number of subjects: 12
Study 9692655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7841566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 0.4 mg/h
Number of subjects: 61
Study 7841566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 1 mg/h
Number of subjects: 61
Study 7841566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 2 mg/h
Number of subjects: 61
Study 7841566 — intervention group
Group type: COMPARATOR
Intervention: Vehicle 10 mL/h
Number of subjects: 61
Study 7841566 — intervention group
Group type: COMPARATOR
Intervention: Placebo 10 mL/h
Number of subjects: 61
Study 7841566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 0.4 mg/h and 1 mg/h
Number of subjects: 61
Study 3073766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial infusion therapy with prostaglandin E1 (PGE)
Number of subjects: 40
Study 3073766 — intervention group
Group type: COMPARATOR
Intervention: Infusion therapy with energy rich phosphates (ERP)
Number of subjects: 40
Study 29968385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of oral drotaverine hydrochloride (80 mg) and paracetamol (500 mg)
Number of subjects: 252
Study 29968385 — intervention group
Group type: COMPARATOR
Intervention: Oral paracetamol (500 mg) three times a day for 3 days
Number of subjects: 252
Study 28448784 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) telephone intervention conducted by pharmacy students, including an initial call and 5 monthly follow-up calls.
Number of subjects: 743
Study 28448784 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) telephone intervention conducted by pharmacy students.
Number of subjects: 743
Study 28448784 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI intervention).
Number of subjects: 743
Study 25614134 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 0
Study 25614134 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace (lateral counterforce brace)
Number of subjects: 0
Study 25614134 — intervention group
Group type: COMPARATOR
Intervention: Placebo HILT (sham therapy group)
Number of subjects: 0
Study 23924198 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge plate surgery
Number of subjects: 110
Study 23924198 — intervention group
Group type: COMPARATOR
Intervention: Functional brace
Number of subjects: 110
Study 21044518 — intervention group
Group type: EXPERIMENTAL
Intervention: Copy the target word from the computer screen (n=22)
Number of subjects: 85
Study 21044518 — intervention group
Group type: EXPERIMENTAL
Intervention: Memorize the target word and write it from memory (n=21)
Number of subjects: 85
Study 21044518 — intervention group
Group type: EXPERIMENTAL
Intervention: Word reading (n=21)
Number of subjects: 85
Study 21044518 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group (n=21)
Number of subjects: 85
Study 18459541 — intervention group
Group type: EXPERIMENTAL
Intervention: Piver type II hysterectomy
Number of subjects: 0
Study 17052306 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg (for patients aged<11 years) or 400 microg administered via Turbuhaler
Number of subjects: 6656
Study 17052306 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus usual asthma therapy
Number of subjects: 6656
Study 14641507 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 326
Study 14641507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 11011847 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid, 0.4 mg vitamin B12 and 50 mg vitamin B6
Number of subjects: 600
Study 11011847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 9309533 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/die orally for 7 days
Number of subjects: 14
Study 9309533 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 14
Study 8339552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary changes alone
Number of subjects: 219
Study 8339552 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 219
Study 8339552 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dietary changes and exercise
Number of subjects: 219
Study 8339552 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 219
Study 3730230 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.15, 0.2 or 0.3 mg kg‐1 with priming
Number of subjects: 72
Study 3730230 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.04 mg kg‐1 given 30 s after induction
Number of subjects: 72
Study 3730230 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.3 mg kg‐1 with increased priming portion
Number of subjects: 72
Study 29504342 — intervention group
Group type: EXPERIMENTAL
Intervention: Physio dispenser group
Number of subjects: 60
Study 29504342 — intervention group
Group type: COMPARATOR
Intervention: Slow speed handpiece group
Number of subjects: 60
Study 27388213 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction using a distally inserted hamstring graft (HG) with tibial insertion preservation
Number of subjects: 40
Study 27388213 — intervention group
Group type: COMPARATOR
Intervention: ACL reconstruction with hamstring graft (HG) tibial detachment
Number of subjects: 40
Study 25008027 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5-mg
Number of subjects: 195
Study 25008027 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10-mg
Number of subjects: 195